vs
Opus Genetics, Inc.（IRD）与Lakeside Holding Ltd（LSH）财务数据对比。点击上方公司名可切换其他公司
Lakeside Holding Ltd的季度营收约是Opus Genetics, Inc.的1.8倍（$7.0M vs $3.9M），Lakeside Holding Ltd同比增速更快（95.0% vs -10.2%）
Opus Genetics是一家临床阶段生物技术企业，专注开发针对遗传性视网膜疾病的靶向基因疗法，致力于为患有罕见致盲性眼部疾病的患者解决未被满足的医疗需求，核心业务为面向全球罕见病市场推进可及性治疗候选药物的研发工作。
莱克赛德出版社是位于美国芝加哥的出版品牌，由RR唐纳利公司运营。该社除了出版高品质书籍外，还承印邮购目录、电话号码簿、百科全书与广告宣传品，最为人熟知的是为芝加哥卡克斯顿俱乐部出版的高端版本，以及经典重印丛书《莱克赛德经典》。
IRD vs LSH — 直观对比
营收规模更大
LSH
是对方的1.8倍
$3.9M
营收增速更快
LSH
高出105.2%
-10.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.9M | $7.0M |
| 净利润 | — | $-1.6M |
| 毛利率 | — | 27.2% |
| 营业利润率 | — | -21.3% |
| 净利率 | — | -22.6% |
| 营收同比 | -10.2% | 95.0% |
| 净利润同比 | 53.0% | 18.7% |
| 每股收益（稀释后） | — | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IRDLSH
| Q4 25 | $3.9M | $7.0M | ||
| Q3 25 | $3.1M | $6.1M | ||
| Q2 25 | $2.9M | $6.3M | ||
| Q1 25 | $4.4M | $3.8M | ||
| Q4 24 | $4.3M | $3.6M | ||
| Q3 24 | $3.9M | $4.1M | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $1.7M | — |
净利润IRDLSH
| Q4 25 | — | $-1.6M | ||
| Q3 25 | $-17.5M | $-1.4M | ||
| Q2 25 | $-7.4M | $-893.1K | ||
| Q1 25 | $-8.2M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-7.5M | $-1.3M | ||
| Q2 24 | $-7.8M | — | ||
| Q1 24 | $-7.1M | — |
毛利率IRDLSH
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 18.2% | ||
| Q2 25 | — | 26.7% | ||
| Q1 25 | — | 18.8% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率IRDLSH
| Q4 25 | — | -21.3% | ||
| Q3 25 | -269.9% | -20.8% | ||
| Q2 25 | -309.0% | -8.9% | ||
| Q1 25 | -227.2% | -28.2% | ||
| Q4 24 | — | -55.6% | ||
| Q3 24 | -207.1% | -32.5% | ||
| Q2 24 | -748.9% | — | ||
| Q1 24 | -450.5% | — |
净利率IRDLSH
| Q4 25 | — | -22.6% | ||
| Q3 25 | -566.9% | -22.2% | ||
| Q2 25 | -257.5% | -14.2% | ||
| Q1 25 | -187.5% | -28.2% | ||
| Q4 24 | — | -54.1% | ||
| Q3 24 | -194.6% | -32.7% | ||
| Q2 24 | -698.3% | — | ||
| Q1 24 | -415.3% | — |
每股收益（稀释后）IRDLSH
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.25 | $-0.09 | ||
| Q2 25 | $-0.12 | $-0.11 | ||
| Q1 25 | $-0.24 | $-0.14 | ||
| Q4 24 | — | $-0.26 | ||
| Q3 24 | $-0.29 | $-0.18 | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.29 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $45.1M | $1.6M |
| 总债务越低越好 | — | $2.4M |
| 股东权益账面价值 | $15.3M | $12.2M |
| 总资产 | $50.2M | $24.3M |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资IRDLSH
| Q4 25 | $45.1M | $1.6M | ||
| Q3 25 | $30.8M | $4.5M | ||
| Q2 25 | $32.4M | $5.0M | ||
| Q1 25 | $41.8M | $1.5M | ||
| Q4 24 | $30.3M | $1.1M | ||
| Q3 24 | $36.6M | $2.7M | ||
| Q2 24 | $41.4M | — | ||
| Q1 24 | $47.2M | — |
总债务IRDLSH
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | — | $774.2K | ||
| Q4 24 | — | $784.8K | ||
| Q3 24 | — | $589.9K | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益IRDLSH
| Q4 25 | $15.3M | $12.2M | ||
| Q3 25 | $6.0M | $7.0M | ||
| Q2 25 | $17.5M | $2.8M | ||
| Q1 25 | $5.1M | $749.8K | ||
| Q4 24 | $6.7M | $1.6M | ||
| Q3 24 | $34.3M | $3.6M | ||
| Q2 24 | $40.6M | — | ||
| Q1 24 | $46.1M | — |
总资产IRDLSH
| Q4 25 | $50.2M | $24.3M | ||
| Q3 25 | $36.1M | $18.6M | ||
| Q2 25 | $38.7M | $14.4M | ||
| Q1 25 | $48.2M | $9.9M | ||
| Q4 24 | $36.9M | $9.8M | ||
| Q3 24 | $40.4M | $10.8M | ||
| Q2 24 | $44.8M | — | ||
| Q1 24 | $51.8M | — |
负债/权益比IRDLSH
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 1.03× | ||
| Q4 24 | — | 0.48× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-35.3M | $-453.5K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流IRDLSH
| Q4 25 | $-35.3M | $-453.5K | ||
| Q3 25 | $-6.2M | $-4.0M | ||
| Q2 25 | $-10.3M | $-483.7K | ||
| Q1 25 | $-9.0M | $-238.3K | ||
| Q4 24 | $-25.6M | $-530.2K | ||
| Q3 24 | $-5.1M | $-1.4M | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $-5.7M | — |
自由现金流IRDLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-497.4K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-560.5K | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率IRDLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -15.6% | ||
| Q3 24 | — | -34.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度IRDLSH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IRD
暂无分部数据
LSH
| Transferred Over Time | $4.6M | 65% |
| Distribution Of Pharmaceutical Products | $2.4M | 35% |
